News >

No Reduction in HRQOL With Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Jason Harris
Published: Monday, Jan 15, 2018

Neoadjuvant chemoradiotherapy (nCRT) did not lower postoperative health-related quality of life (HRQOL) compared with surgery alone for patients with esophageal or junctional cancer, according to results from the phase III CROSS trial reported in the Journal of Clinical Oncology.1

<.001; CD, 0.52; 95% CI, 0.38-0.65).


  1. Noordman BJ, Verdam MGE, Lagarde SM, et al. Effect of neoadjuvant chemoradiotherapy on health-related quality of life in esophageal or junctional cancer: results from the randomized CROSS trial. J Clin Oncol.
  2. Shaprio J, van Lanscot JB, Hulshof, MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090-1098.doi: 10.1016/S1470-2045(15)00040-6.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication